POST-TREATMENT SURVEILLANCE AND MANAGEMENT OF RECURRENT CERVICAL CANCER - A REVIEW FROM THE FRENCH CERVICAL CANCER GUIDELINES GROUP

@article{buffeteau2026posttreatment,
  title = {{POST-TREATMENT SURVEILLANCE AND MANAGEMENT OF RECURRENT CERVICAL CANCER - A REVIEW FROM THE FRENCH CERVICAL CANCER GUIDELINES GROUP}},
  author = {Aurélie Buffeteau and Abel Cordoba and Jean Levêque and Pascal Rousset and Isabelle Thomassin and Jean-Luc Brun and Xavier Carcopino and Lobna Ouldamer and Cyrille Huchon and Pauline Asseeva and Henri Azaïs and Sofiane Bendifallah and Jean-Luc Brun and Geoffroy Canlorbe and Cyrus Chargari and Pauline Chauvet and Abel Cordoba and Hélène Courcier and Yohann Dabi and Marion de Berti and Caroline Diguisto and Eva Fuss and Thomas Gaillard and Tristan Gauthier and Witold Gertych and Laurence Gladieff and Olivier Graesslin and Yohan Kerbage and Martin Koskas and Enora Laas and Aymeline Lacorre and Vincent Lavoué and Lise Lecointre and Fabrice Lecuru and François Margueritte and Alejandra Martinez and Paul-Jean Maternowski and Patrice Mathevet and Imane Menouer and Camille Mimoun and A Moureau and Antoine Netter and Charles-André Philip and Pascal Rousset and Claire Sanson and Isabelle Thomassin-Naggara and Cyril Touboul and Jean Levêque},
  journal = {Journal of Gynecology Obstetrics and Human Reproduction},
  year = {2026},
  month = nov,
  doi = {10.1016/j.jogoh.2026.103315},
  url = {https://hal.science/hal-05850520v1},
  note = {CC BY},
}

TY  - JOUR
TI  - POST-TREATMENT SURVEILLANCE AND MANAGEMENT OF RECURRENT CERVICAL CANCER - A REVIEW FROM THE FRENCH CERVICAL CANCER GUIDELINES GROUP
AU  - Aurélie Buffeteau
AU  - Abel Cordoba
AU  - Jean Levêque
AU  - Pascal Rousset
AU  - Isabelle Thomassin
AU  - Jean-Luc Brun
AU  - Xavier Carcopino
AU  - Lobna Ouldamer
AU  - Cyrille Huchon
AU  - Pauline Asseeva
AU  - Henri Azaïs
AU  - Sofiane Bendifallah
AU  - Jean-Luc Brun
AU  - Geoffroy Canlorbe
AU  - Cyrus Chargari
AU  - Pauline Chauvet
AU  - Abel Cordoba
AU  - Hélène Courcier
AU  - Yohann Dabi
AU  - Marion de Berti
AU  - Caroline Diguisto
AU  - Eva Fuss
AU  - Thomas Gaillard
AU  - Tristan Gauthier
AU  - Witold Gertych
AU  - Laurence Gladieff
AU  - Olivier Graesslin
AU  - Yohan Kerbage
AU  - Martin Koskas
AU  - Enora Laas
AU  - Aymeline Lacorre
AU  - Vincent Lavoué
AU  - Lise Lecointre
AU  - Fabrice Lecuru
AU  - François Margueritte
AU  - Alejandra Martinez
AU  - Paul-Jean Maternowski
AU  - Patrice Mathevet
AU  - Imane Menouer
AU  - Camille Mimoun
AU  - A Moureau
AU  - Antoine Netter
AU  - Charles-André Philip
AU  - Pascal Rousset
AU  - Claire Sanson
AU  - Isabelle Thomassin-Naggara
AU  - Cyril Touboul
AU  - Jean Levêque
PY  - 2026
DA  - 2026/11/03
JO  - Journal of Gynecology Obstetrics and Human Reproduction
DO  - 10.1016/j.jogoh.2026.103315
UR  - https://hal.science/hal-05850520v1
AB  - OBJECTIVE: To review the available evidence on post-treatment follow-up and recurrence management after cervical cancer. METHODS: We conducted a narrative review of the literature on surveillance modalities, and the management of pelvic and nodal recurrences. RESULTS: Most recurrences occur within three years of treatment, but the survival benefit of detection before symptom onset remains unproven. After fertility-sparing surgery, HPV testing is sensitive for detecting asymptomatic pelvic recurrence. After hysterectomy, most recurrences are symptomatic, and clinical examination has a higher diagnostic yield than HPV testing or vaginal vault cytology. After concurrent chemoradiotherapy (CRT), persistent HPV infection is associated with an increased recurrence risk, but its limited specificity and the absence of a validated HPV-based surveillance strategy restrict its clinical utility. MRI and FDG PET/CT are useful for response assessment and investigation of suspected recurrence, but evidence supporting routine imaging of asymptomatic patients is lacking. Intensive follow-up schedules have not improved recurrence detection or survival. Evidence on recurrence management is predominantly retrospective. Pelvic recurrences after primary surgery have been treated with CRT, supplemented by brachytherapy for vaginal involvement. In selected patients with central pelvic recurrence after CRT, complete surgical resection may provide prolonged survival, but carries substantial morbidity. Nodal recurrences outside previously irradiated fields have been treated with CRT. CONCLUSION: Available evidence supports a predominantly clinical, treatment-adapted follow-up. The survival benefit of intensive surveillance, routine imaging, or detecting asymptomatic recurrence remains uncertain. Recurrence management requires individualized multidisciplinary assessment based on disease extent, disease-free interval, and previous treatments.
SN  - 2468-8495
SN  - 2468-7847
ER  -